Sustained proteasome inhibition by carfilzomib, a selective proteasome inhibitor, enhances anti-tumor activity

被引：0
|
作者：
Aujay, Monette [1 ]
Demo, Susan [1 ]
Jiang, Jing [1 ]
Kirk, Christopher [1 ]
Parlati, Francesco [1 ]
Suzuki, Erika [1 ]
Woo, Tina [1 ]
Bennett, Mark [1 ]
机构：
[1] Proteolix, San Francisco, CA USA
来源：
CANCER RESEARCH | 2009年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4538
引用
收藏
页数：1
相关论文
共 50 条
  • [1] The selective proteasome inhibitor carfilzomib in combination with chemotherapeutic agents improves anti-tumor response in solid tumor xenograft models
    Dajee, M.
    Aujay, M.
    Demo, S.
    Jiang, J.
    Kirk, C.
    Lee, S.
    Parlati, F.
    Sheilds, J.
    Sun, M.
    Suzuki, E.
    [J]. EJC SUPPLEMENTS, 2008, 6 (12): : 75 - 75
  • [2] Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer
    Nakata, Wachiko
    Hayakawa, Yoku
    Nakagawa, Hayato
    Sakamoto, Kei
    Kinoshita, Hiroto
    Takahashi, Ryota
    Hirata, Yoshihiro
    Maeda, Shin
    Koike, Kazuhiko
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 2011, 39 (06) : 1529 - 1536
  • [3] Anti-Tumor Activity of the Proteasome Inhibitor Bortezomib in Gastric Cancer
    Nakata, Wachiko
    Hayakawa, Yoku
    Nakagawa, Hayato
    Sakamoto, Kei
    Kinoshita, Hiroto
    Takahashi, Ryota
    Hirata, Yoshihiro
    Maeda, Shin
    Koike, Kazuhiko
    [J]. GASTROENTEROLOGY, 2011, 140 (05) : S674 - S674
  • [4] Anti-tumor action and clinical application of proteasome inhibitor
    Zhou Yong-ming
    Yu Mei-xia
    Long Hui
    Huang Shi-ang
    [J]. CHINESE JOURNAL OF CANCER RESEARCH, 2008, 20 (02) : 77 - 84
  • [5] Anti-tumor Action and Clinical Application of Proteasome Inhibitor
    周咏明
    余美霞
    龙辉
    黄士昂
    [J]. Chinese Journal of Cancer Research, 2008, (02) : 77 - 84
  • [6] Anti-tumor effect of proteasome inhibitor on canine urothelial carcinoma
    Kodera, Yuka
    Iguchi, Takaaki
    Kato, Daiki
    Ikeda, Namiko
    Shinada, Masahiro
    Aoki, Susumu
    Soga, Kyoka
    Li, Toshio
    Ohata, Ryosuke
    Koseki, Shoma
    Shibahara, Hayato
    Takahashi, Yosuke
    Hashimoto, Yuko
    Nishimura, Ryohei
    Nakagawa, Takayuki
    [J]. JOURNAL OF VETERINARY MEDICAL SCIENCE, 2024, 86 (09): : 961 - 965
  • [7] Proteasome Maturation Protein (pomp) Is Associated With Proteasome Inhibitor Resistance In Myeloma, and Its Suppression Enhances The Activity Of Bortezomib and Carfilzomib
    Li, Bingzong
    Wang, Hua
    Orlowski, Robert Z.
    [J]. BLOOD, 2013, 122 (21)
  • [8] Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
    Xuxing Shen
    Chao Wu
    Meng Lei
    Qing Yan
    Haoyang Zhang
    Lina Zhang
    Xueyuan Wang
    Ye Yang
    Jianyong Li
    Yongqiang Zhu
    Lijuan Chen
    [J]. Cell Death & Disease, 12
  • [9] Anti-tumor activity of a novel proteasome inhibitor D395 against multiple myeloma and its lower cardiotoxicity compared with carfilzomib
    Shen, Xuxing
    Wu, Chao
    Lei, Meng
    Yan, Qing
    Zhang, Haoyang
    Zhang, Lina
    Wang, Xueyuan
    Yang, Ye
    Li, Jianyong
    Zhu, Yongqiang
    Chen, Lijuan
    [J]. CELL DEATH & DISEASE, 2021, 12 (05)
  • [10] Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome
    Parlati, Francesco
    Lee, Susan J.
    Aujay, Monette
    Suzuki, Erika
    Levitsky, Konstantin
    Lorens, James B.
    Micklem, David R.
    Ruurs, Paulina
    Sylvain, Catherine
    Lu, Yan
    Shenk, Kevin D.
    Bennett, Mark K.
    [J]. BLOOD, 2009, 114 (16) : 3439 - 3447
12345